Reactogenicity and immunogenicity of reduced antigen content diphtheria-tetanus-acellular pertussis vaccine (dTpa) administered as a booster to 4-6 year-old children primed with four doses of whole-cell pertussis vaccine

Vaccine

Volumn 21, Issue 27-30, 2003, Pages 4194-4200

  Kosuwon, Pensri ^a   Warachit, Boonyarat ^b   Hutagalung, Yanee ^c   Borkird, Thitiporn ^b   Kosalaraksa, Pope ^a   Bock, Hans L ^c   Poovorawan, Yong ^d  

^a KHON KAEN UNIVERSITY   (Thailand)

^b HATYAI HOSPITAL   (Thailand)

^c GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

^d KING CHULALONGKORN MEMORIAL HOSPITAL   (Thailand)

Author keywords

Booster; DTPa; Immunogenicity; Reactogenicity

Indexed keywords

ANTIGEN; BACTERIAL VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; DIPHTHERIA TETANUS WHOLE CELL PERTUSSIS VACCINE; HEMAGGLUTININ; PERTACTIN; PERTUSSIS TOXIN; UNCLASSIFIED DRUG;

APPETITE DISORDER; ARTICLE; CHILDHOOD DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIPHTHERIA; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG ACTIVITY; DRUG TOLERABILITY; EDEMA; ERYTHEMA; FEMALE; FEVER; HUMAN; IMMUNIZATION; IMMUNOGENICITY; INFECTION PREVENTION; IRRITABILITY; MALE; NORMAL HUMAN; PAIN; PERTUSSIS; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REACTOGENICITY; SIDE EFFECT; STATISTICAL SIGNIFICANCE; TETANUS; THAILAND; TREATMENT OUTCOME; VACCINATION;

EID: 0347448155     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(03)00496-1     Document Type: Article

References (41)

1. Bland J., Clements J. Protecting the world's children: the story of WHO's immunization programme. World Health Forum. 19:1998;162-173.
2. Barkin R.M., Pichichero M.E. Diptheria-pertussis-tetanus vaccine: reactogenicity of commercial products. Pediatrics. 45:1979;4245-4252.
3. Robinson A., Funnell S.G.P. Potency testing of acellular pertussis vaccines. Vaccine. 10:1992;139-141.
4. Kulenkampff M., Schwartzman J.S., Wilson J. Neurological complications of pertussis inoculation. Arch. Dis. Child. 49:1974;46-49.
5. Miller D.L., Ross E.M., Alderslade R., Bellman M.H., Rawson N.S.B. Pertussis immunization and serious acute neurological illness in children. Br. Med. J. 282:1981;1595-1599.
6. Cherry J.D. The epidemiology of pertussis immunization in the UK and the US: a comparative study. Curr. Probl. Pediatr. 14:1984;1-78.
7. Noble G.R., Bernier R.H., Esber E.C.et al. Acellular and whole cell pertussis vaccines in Japan: report of a visit by US scientists. JAMA. 257:1987;1351-1356.
8. Romanus V., Jonsell R., Bergquist S.O. Pertussis in Sweden after the cessation of general immunization in 1979. Pediatr. Infect. Dis. J. 6:1987;364-371.
9. Finger H., Wirsing von Konig C.-H., Tacken A., Wassilak S.G.F. The epidemiology situation of pertussis in the Federal Republic of Germany. Dev. Biol. Stand. 73:1991;343-355.
10. Marwick C. Changes ahead in childhood immunization. JAMA. 275:1996;582.
11. Rosenthal S., Robert C., Hadler S. The safety of acellular pertussis vaccine vs. whole-cell pertussis vaccine. Arch. Pediatr. Adolesc. Med. 150:1996;460.
12. Halperin S.A., Eastwood B.J., Barreto L., Friesen B., Medd L., Meekison W.et al. Adverse reactions and antibody response to four doses of acellular or whole cell pertussis vaccine combined with diphtheria and tetanus toxoids in the first 19 months of life. Vaccine. 14:1996;767-772.
13. Greco D., Salmaso S., Mastrantonio P., Giuliano M., Tozzi A.E., Anemona A. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. N. Eng. J. Med. 334:1996;341-348.
14. Gustafsson L., Hallander H.O., Olin P., Reizebstein E., Stirsaeter J. A control trial of a two component acellular, a five-component acellular, and a whole-cell pertussis vaccine. N. Eng. J. Med. 334:1996;349-355.
15. Schmitt H.-J., Wirsing von King C.H., Neiss A. Efficacy of acellular pertussis vaccine in early childhood after household exposure. JAMA. 275:1996;37-42.
16. American Academic of Pediatrics Committee on Infectious Disease. Acellular pertussis vaccine: recommendations for use as the initial series in infants and children. Pediatrics 1997;99:282-8.
17. Edward K.M. Acellular petussis vaccines - a solution to the pertussis problem? J. Infect. Dis. 168:1993;15-20.
18. National Health and Medical Research Council. The Australian immunization handbook. 7th ed. Canberra: Commonwealth of Australia; 2000.
19. Tozzi A.E., Anemona A., Stat D., Stefanelli P., Biol D., Salmoso S.et al. Reactogenicity and immunogenicity at preschool age of a booster dose of two three-component diphtheria-tetanus-acellular pertussis vaccines in children primed in infancy with acellular vaccines. Pediatrics. 107:2001;1-9.
20. Ciofi-degli-Atti M.L., Anenoma A., Tozzi A.E., Stefanelli P., Giammanco A., Salmaso S. Reactogenicity of the three-dose pertussis acellular vaccine catch-up in children 21-40 month of age. Vaccine. 17:1999;2030-2035.
21. Pichichero M.E., Green J.L., Francis A.B., Marsocci S.M., Murphy A.M.L., Buscarino C. Antibody response and reactions to completion of a four-dose series with a two- or three-component acellular pertussis vaccine compared to whole cell pertussis vaccine. Scand. J. Infect. Dis. 28:1996;159-163.
22. Efstratiou A, Maple PAC. Laboratory diagnosis of diphtheria. Copenhagen: The Expanded Program on Immunization in the European Region of WHO; 1994.
23. Ipsen J., Bowen H.E. Effect of routine immunization of children with triple vaccine (diphtheria-tetanus-pertussis). Am. J. Public Health. 45:1955;312-318.
24. Pichicero M.E., Anderson E.L., Rennels M.B. Fifth vaccination with diphtheria, tetanus and acellular pertussis is beneficial in four-to six-year-olds. Pediatr. Infect. Dis. J. 20:2001;427-433.
25. Edwards K.M., Lawrence E., Wright P. Diphtheria, tetanus, and pertussis vaccine - a comparison of the immune response and adverse reactions to conventional and acellular pertussis components. Am. J. Dis. Child. 140:1986;867-871.
26. Lewis K., Cherry J.D., Holroyd H.J., Baker L.R., Dudenhoeffer F.R., Robinson R.G. A double-blind study comparing an acellular pertussis-component DTP vaccine with a whole-cell pertussis-component DTP vaccine in 18-month-old children. Am. J. Dis. Child. 140:1986;872-876.
27. Center for Disease Control and Prevention. Pertussis vaccination - acellular pertussis vaccine for the fourth and fifth doses of the DTP series: update to supplementary ACIP statement, recommendations of the Advisory Committee on Immunization Practices (ACIP). CDC surveillance summary. MMWR Morb Mortal Wkly Rep 1992;41:1-5.
28. Dagan R., Igbaria K., Piglansky L., Brusteghem F.V., Melot V., Kaufhold A. Reactogenicity and immunogenicity of reduced antigen content diphtheria-tetanus-acellular pertussis vaccines as a booster in 4-7-year-old children primed with diphtheria-tetanus-whole cell pertussis vaccine before 2 years of age. Vaccine. 17:1999;2620-2627.
29. Annunziato P.W., Rothstein E.P., Bernstein H.H., Blatter M.M., Reisinger K.S., Pichichero M.E. Comparison of a three-component acellular pertussis vaccine with a whole-cell pertussis vaccine in 4-through 6-year-old children. Arch. Pediatr. Adolesc. Med. 148:1994;503-507.
30. Pichichero M.E., Edwards K.M., Anderson E.L., Renneks M.B., Englund J.A., Yerg D.E. Safety and immunogenicity of six acellular pertussis vaccine and one whole-cell pertussis vaccine given as a fifth dose in four-to six-year-old children. Pediatrics. 105:2000;1-8.
31. Halperin S.A., Scheifele D., Barreto L., Pim C., Guasparini R., Medd L. Comparison of a fifth dose of a five-component acellular or a whole cell pertussis vaccine in children four to six years of age. Pediatr. Infect. Dis. J. 18:1999;772-779.
32. Storsaeter J., Hallander H., Gustafsson L., Olin P. Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis. Vaccine. 16:1998;1907-1916.
33. Cherry J.D., Gornbein J., Heininger U., Stehr K. A search for serologic correlates of immunity to Bordetella pertussis cough illnesses. Vaccine. 16:1998;1901-1906.
34. Weiss A.A., Hewlett E.L., Myer G.A., Felkows S. Pertussis toxin and extracytoplasmic adenylate cyclase as virulence factors of Bordetella pertussis. J. Infect. Dis. 150:1984;219-222.
35. Pittman M. The concept of pertussis as a toxin-mediated disease. Pediatr. Infect. Dis. J. 3:1984;1984-1986.
36. Ausiello C.M., Lande R., Urbani F., Di Carlo B., Stefanelli P., Salmaso S.et al. Cell-mediated immunity and antibody responses to Bordetella pertussis antigens in children with a history of pertussis infection and in recipients of an acellular pertussis vaccine. J. Infect. Dis. 181:2000;1989-1995.
37. Zepp F., Knuf M., Habermehl P., Schmitt J.H., Rebsch C., Schmidtke P.et al. Pertussis-specific cell-mediated immunity in infants after vaccination with a tricomponent acellular pertussis vaccine. Infect. Immun. 64:1996;4078-4084.
38. Ryan M., Murphy G., Ryan E., Nilsson L., Shackley F., Gothefors L.et al. Distinct T-cell subtypes induced with whole cell and acellular pertussis vaccines in children. Immunology. 93:1998;1-10.
39. Esposito S., Agliardi T., Giammanco A., Faldella G., Cascio A., Bosis S.et al. Long-term pertussis-specific immunity after primary vaccination with a combined diphtheria, tetanus, tricomponent acellular pertussis, and hepatitis B vaccine in comparison with that after natural infection. Infect. Immun. 69:2001;4516-4520.
40. Nicoly U., Girgsdies O.E., Banzhoff A., Hundt E., Jily W. Diphtheia booster vaccination one or two injections. Vaccine. 17:1999;2223-2228.
41. Ciofi-degli-Atti M.L., Salmaso S., Cotter B., Gallo G., Alfarone G., Pinto A.et al. Reactogenicity and immunogenicity of adult versus paediatric diphtheria and teanus booster dose at 6 years of age. Vaccine. 20:2002;74-79.